Covishield found ineffective against Omicron, booster a must: Study

The ICMR-NIV), Pune, has reported a case of three-time Covid infection in an individual who was vaccinated with the Covishield jab against the virus.

Covishield
(Photo: PTI)
IANS New Delhi
2 min read Last Updated : Apr 24 2022 | 4:04 PM IST

The Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, has reported a case of three-time Covid infection in an individual who was vaccinated with the Covishield jab against the virus.

The healthcare professional from Delhi had primary SARS-CoV2 infection, breakthrough infection with Delta and reinfection with Omicron over a period of around 16 months, researchers of Pune NIV said in a study.

The findings of the study prove the immune evasion potential of the Omicron variant, even after infection and vaccination, said the researchers.

The researchers in the report have said that the 38-year-old had tested positive with primary Covid infection during the first wave of the pandemic with symptoms like body ache, fever and a dry cough on October 9, 2020.

However, there were no complaints of breathlessness, and post recovery, he experienced symptoms of long Covid, including generalised weakness for two to three weeks and insomnia for two to three months.

The healthcare professional experienced body ache and headache again in November 2021. Subsequently, he tested positive for SARS-COV-2 and the body ache persisted for two to three days.

However, during the third wave of the pandemic, the individual again developed a headache on January 24, 2022, after being asymptomatic for a period of two months.

The researchers in the report said that the case represented a breakthrough infection post primary SARS-CoV-2 infection and two doses of Covishield vaccination.

The patient received the first dose of Covishield vaccine on January 31, 2021, and the second dose on March 3.

While vaccination reportedly reduces severity of disease and mortality in Covid-19, it cannot protect individuals from getting a breakthrough infection, said the researchers.

The NIV scientists concluded the report saying that the fight against Covid-19 is far from over. Although vaccine boosters or third doses have shown an augmentation in the immune response against the Omicron variant, it has been found to wane over time.

In such a situation, non-pharmacological interventions in the form of mask, hand hygiene and infection control remain the most reliable weapons to curb the direct transmission of SARS-CoV-2, researchers said in the report. The report was published in the Journal of Infection.

--IANS

avr/ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusOmicronDelta variant of coronavirusCoronavirus Vaccine

First Published: Apr 24 2022 | 4:04 PM IST

Next Story